We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite official data suggesting that generics now account for some 17% of Brazil's drug market -- with a value of US$1.5bn -- local reports claim that distribution is not even across the country, and there is still tough competition from non-bioequivalent copies.
Italy's Health Minister is to meet with Italian consumer groups in order to discuss new price controls for "Class C," or non-reimbursed, drugs, which include both OTC and some prescription products.
India's biotech industry could reap the benefits as 11 blockbuster drugs lose patent protection in 2006. Major products facing patent expiry include anaemia treatment Epogen and insulin products Novolin and Humulin.
Jenburkt Pharmaceuticals (Q, N,C,F)* Ltd members have approved declaration of dividend of 10 per cent that is Re 1.00 per share on equity shares of Rs 10 paid up, for the year ended March 31, 2005.
OPi SA, Pharmaceuticals for Rare Diseases and the UK Health Protection Agency (HPA) announce today that they have entered into a world-wide licensing and supply agreement on Erwinase(R) (crisantaspase), L-asparaginase derived from Erwinia chrysanthemi.
Tanzania's business community threatened today to sue Kenya for breaking the rules of a customs union reached earlier this year, after Finance minister David Mwiraria zero-rated imports of pharmaceutical products.
DRAXIS Health Inc. (TSX: DAX) (Nasdaq: DRAX) has extended the period before it will resume production of sterile and lyophilized products at DRAXIS Pharma, its pharmaceutical contract manufacturing division, as part of its regular summer shutdown for maintenance.
St. Paul Pharmaceutical, a pending merger partner with WENR Corp. (OTC:WNRC) (wenr.net), announced today that it signed a distribution agreement with Akzo Nobel of the Netherlands to distribute Ferrazone(R) to countries in southeast Asia. St. Paul's agreement includes the distribution of Ferrazone(R) in Viet Nam, Cambodia and Laos with a potential market of over 100 million people. Ferrazone(R) is Akzo Nobel's brand name for sodium iron (III) ethylenediaminetetraacetate
(NaFeEDTA).